Growing RSV incidence, increased awareness of monoclonal therapies, expanding NICUs, and reimbursement drive growth. Future opportunities include next-gen RSV prevention, increased biologic manufacturing, and precision immunotherapy. Regional biologics produc…
Dublin, March 09, 2026 (GLOBE NEWSWIRE) -- The "Synagis Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering.
The… [+7314 chars]
.jpeg?trim=0,1,0,0&width=1200&height=800&crop=1200:800)
